BIOS Fund III, LP reports a stock award at ACTU
By AlphaYouPublished Form 4
BIOS Fund III, LP; BIOS Fund III QP, LP; BIOS Fund III NT, LP
Reporting filer
BIOS Fund III, LP reports a stock award, not an open-market purchase or sale, in Actuate Therapeutics, Inc.. Form 4 filed Oct 30, 2026 lists 13 entries.
- Disclosed
- Oct 30, 2026
Reported details
13 entries| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Warrant (Right to Buy) (derivative) | BIOS Fund III, LP; BIOS Fund III QP, LP; BIOS Fund III NT, LP | 2026-10-28 | A | Grant or award | 64995 | 0 | 64,995 | 2 days | Filed terms
|
| Warrant (Right to Buy) (derivative) | BIOS Fund III, LP; BIOS Fund III QP, LP; BIOS Fund III NT, LP | 2026-10-28 | A | Grant or award | 87743 | 0 | 87,743 | 2 days | Filed terms
|
| Warrant (Right to Buy) (derivative) | BIOS Fund III, LP; BIOS Fund III QP, LP; BIOS Fund III NT, LP | 2026-10-28 | A | Grant or award | 682885 | 0 | 682,885 | 2 days | Filed terms
|
| Warrant (Right to Buy) (derivative) | BIOS Fund III, LP; BIOS Fund III QP, LP; BIOS Fund III NT, LP | 2026-10-28 | A | Grant or award | 194984 | 0 | 194,984 | 2 days | Filed terms
|
| Warrant (Right to Buy) (derivative) | BIOS Fund III, LP; BIOS Fund III QP, LP; BIOS Fund III NT, LP | 2026-10-28 | A | Grant or award | 368304 | 0 | 368,304 | 2 days | Filed terms
|
| Warrant (Right to Buy) (derivative) | BIOS Fund III, LP; BIOS Fund III QP, LP; BIOS Fund III NT, LP | 2026-10-28 | A | Grant or award | 47972 | 0 | 47,972 | 2 days | Filed terms
|
| Warrant (Right to Buy) (derivative) | BIOS Fund III, LP; BIOS Fund III QP, LP; BIOS Fund III NT, LP | 2026-10-28 | A | Grant or award | 82018 | 0 | 82,018 | 2 days | Filed terms
|
| Warrant (Right to Buy) (derivative) | BIOS Fund III, LP; BIOS Fund III QP, LP; BIOS Fund III NT, LP | 2026-10-28 | A | Grant or award | 36056 | 0 | 36,056 | 2 days | Filed terms
|
| Warrant (Right to Buy) (derivative) | BIOS Fund III, LP; BIOS Fund III QP, LP; BIOS Fund III NT, LP | 2026-10-28 | A | Grant or award | 269342 | 0 | 269,342 | 2 days | Filed terms
|
| Warrant (Right to Buy) (derivative) | BIOS Fund III, LP; BIOS Fund III QP, LP; BIOS Fund III NT, LP | 2026-10-28 | A | Grant or award | 82454 | 0 | 82,454 | 2 days | Filed terms
|
| Warrant (Right to Buy) (derivative) | BIOS Fund III, LP; BIOS Fund III QP, LP; BIOS Fund III NT, LP | 2026-10-28 | A | Grant or award | 133073 | 0 | 133,073 | 2 days | Filed terms
|
| Warrant (Right to Buy) (derivative) | BIOS Fund III, LP; BIOS Fund III QP, LP; BIOS Fund III NT, LP | 2026-10-28 | A | Grant or award | 824012 | 0 | 824,012 | 2 days | Filed terms
|
| Warrant (Right to Buy) (derivative) | BIOS Fund III, LP; BIOS Fund III QP, LP; BIOS Fund III NT, LP | 2026-10-28 | A | Grant or award | 126162 | 0 | 126,162 | 2 days | Filed terms
|
Warrant (Right to Buy) (derivative)
- Owner
- BIOS Fund III, LP; BIOS Fund III QP, LP; BIOS Fund III NT, LP
- Date
- 2026-10-28
- Code
- A
- Action
- Grant or award
- Quantity
- 64995
- Price
- 0
- Following holdings
- 64,995
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Warrant (Right to Buy)
- conversion Or Exercise Price: 0.5325
- transaction Date: 2026-10-28
- transaction Form Type: 4
- transaction Code: A
- equity Swap Involved: 0
- id: F1
- transaction Timeliness:
- transaction Shares: 64995
- transaction Price Per Share: 0
- transaction Acquired Disposed Code: A
- exercise Date: 2026-10-28
- id: F2
- expiration Date: 2031-10-28
- id: F2
- underlying Security Title: Common Stock
- underlying Security Shares: 64995
- shares Owned Following Transaction: 64995
- direct Or Indirect Ownership: I
- nature Of Ownership: Directly held by Bios 2024 Co-Invest, LP
- id: F3
- id: F4
- id: F5
Warrant (Right to Buy) (derivative)
- Owner
- BIOS Fund III, LP; BIOS Fund III QP, LP; BIOS Fund III NT, LP
- Date
- 2026-10-28
- Code
- A
- Action
- Grant or award
- Quantity
- 87743
- Price
- 0
- Following holdings
- 87,743
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Warrant (Right to Buy)
- conversion Or Exercise Price: 0.5325
- transaction Date: 2026-10-28
- transaction Form Type: 4
- transaction Code: A
- equity Swap Involved: 0
- id: F1
- transaction Timeliness:
- transaction Shares: 87743
- transaction Price Per Share: 0
- transaction Acquired Disposed Code: A
- exercise Date: 2026-10-28
- id: F2
- expiration Date: 2031-10-28
- id: F2
- underlying Security Title: Common Stock
- underlying Security Shares: 87743
- shares Owned Following Transaction: 87743
- direct Or Indirect Ownership: I
- nature Of Ownership: Directly held by Bios Actuate Co-Invest I, LP
- id: F3
- id: F4
- id: F5
Warrant (Right to Buy) (derivative)
- Owner
- BIOS Fund III, LP; BIOS Fund III QP, LP; BIOS Fund III NT, LP
- Date
- 2026-10-28
- Code
- A
- Action
- Grant or award
- Quantity
- 682885
- Price
- 0
- Following holdings
- 682,885
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Warrant (Right to Buy)
- conversion Or Exercise Price: 0.5325
- transaction Date: 2026-10-28
- transaction Form Type: 4
- transaction Code: A
- equity Swap Involved: 0
- id: F1
- transaction Timeliness:
- transaction Shares: 682885
- transaction Price Per Share: 0
- transaction Acquired Disposed Code: A
- exercise Date: 2026-10-28
- id: F2
- expiration Date: 2031-10-28
- id: F2
- underlying Security Title: Common Stock
- underlying Security Shares: 682885
- shares Owned Following Transaction: 682885
- direct Or Indirect Ownership: I
- nature Of Ownership: Directly held by Bios Actuate Co-Invest II, LP
- id: F3
- id: F4
- id: F5
Warrant (Right to Buy) (derivative)
- Owner
- BIOS Fund III, LP; BIOS Fund III QP, LP; BIOS Fund III NT, LP
- Date
- 2026-10-28
- Code
- A
- Action
- Grant or award
- Quantity
- 194984
- Price
- 0
- Following holdings
- 194,984
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Warrant (Right to Buy)
- conversion Or Exercise Price: 0.5325
- transaction Date: 2026-10-28
- transaction Form Type: 4
- transaction Code: A
- equity Swap Involved: 0
- id: F1
- transaction Timeliness:
- transaction Shares: 194984
- transaction Price Per Share: 0
- transaction Acquired Disposed Code: A
- exercise Date: 2026-10-28
- id: F2
- expiration Date: 2031-10-28
- id: F2
- underlying Security Title: Common Stock
- underlying Security Shares: 194984
- shares Owned Following Transaction: 194984
- direct Or Indirect Ownership: I
- nature Of Ownership: Directly held by Bios Actuate Co-Invest III, LP
- id: F3
- id: F4
- id: F5
Warrant (Right to Buy) (derivative)
- Owner
- BIOS Fund III, LP; BIOS Fund III QP, LP; BIOS Fund III NT, LP
- Date
- 2026-10-28
- Code
- A
- Action
- Grant or award
- Quantity
- 368304
- Price
- 0
- Following holdings
- 368,304
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Warrant (Right to Buy)
- conversion Or Exercise Price: 0.5325
- transaction Date: 2026-10-28
- transaction Form Type: 4
- transaction Code: A
- equity Swap Involved: 0
- id: F1
- transaction Timeliness:
- transaction Shares: 368304
- transaction Price Per Share: 0
- transaction Acquired Disposed Code: A
- exercise Date: 2026-10-28
- id: F2
- expiration Date: 2031-10-28
- id: F2
- underlying Security Title: Common Stock
- underlying Security Shares: 368304
- shares Owned Following Transaction: 368304
- direct Or Indirect Ownership: I
- nature Of Ownership: Directly held by Bios Clinical Opportunity Fund, LP
- id: F3
- id: F4
- id: F5
Warrant (Right to Buy) (derivative)
- Owner
- BIOS Fund III, LP; BIOS Fund III QP, LP; BIOS Fund III NT, LP
- Date
- 2026-10-28
- Code
- A
- Action
- Grant or award
- Quantity
- 47972
- Price
- 0
- Following holdings
- 47,972
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Warrant (Right to Buy)
- conversion Or Exercise Price: 0.5325
- transaction Date: 2026-10-28
- transaction Form Type: 4
- transaction Code: A
- equity Swap Involved: 0
- id: F1
- transaction Timeliness:
- transaction Shares: 47972
- transaction Price Per Share: 0
- transaction Acquired Disposed Code: A
- exercise Date: 2026-10-28
- id: F2
- expiration Date: 2031-10-28
- id: F2
- underlying Security Title: Common Stock
- underlying Security Shares: 47972
- shares Owned Following Transaction: 47972
- direct Or Indirect Ownership: I
- nature Of Ownership: Directly held by Bios Fund I QP, LP
- id: F3
- id: F4
- id: F5
Warrant (Right to Buy) (derivative)
- Owner
- BIOS Fund III, LP; BIOS Fund III QP, LP; BIOS Fund III NT, LP
- Date
- 2026-10-28
- Code
- A
- Action
- Grant or award
- Quantity
- 82018
- Price
- 0
- Following holdings
- 82,018
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Warrant (Right to Buy)
- conversion Or Exercise Price: 0.5325
- transaction Date: 2026-10-28
- transaction Form Type: 4
- transaction Code: A
- equity Swap Involved: 0
- id: F1
- transaction Timeliness:
- transaction Shares: 82018
- transaction Price Per Share: 0
- transaction Acquired Disposed Code: A
- exercise Date: 2026-10-28
- id: F2
- expiration Date: 2031-10-28
- id: F2
- underlying Security Title: Common Stock
- underlying Security Shares: 82018
- shares Owned Following Transaction: 82018
- direct Or Indirect Ownership: I
- nature Of Ownership: Directly held by Bios Fund I, LP
- id: F3
- id: F4
- id: F5
Warrant (Right to Buy) (derivative)
- Owner
- BIOS Fund III, LP; BIOS Fund III QP, LP; BIOS Fund III NT, LP
- Date
- 2026-10-28
- Code
- A
- Action
- Grant or award
- Quantity
- 36056
- Price
- 0
- Following holdings
- 36,056
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Warrant (Right to Buy)
- conversion Or Exercise Price: 0.5325
- transaction Date: 2026-10-28
- transaction Form Type: 4
- transaction Code: A
- equity Swap Involved: 0
- id: F1
- transaction Timeliness:
- transaction Shares: 36056
- transaction Price Per Share: 0
- transaction Acquired Disposed Code: A
- exercise Date: 2026-10-28
- id: F2
- expiration Date: 2031-10-28
- id: F2
- underlying Security Title: Common Stock
- underlying Security Shares: 36056
- shares Owned Following Transaction: 36056
- direct Or Indirect Ownership: I
- nature Of Ownership: Directly held by Bios Fund II NT, LP
- id: F3
- id: F4
- id: F5
Warrant (Right to Buy) (derivative)
- Owner
- BIOS Fund III, LP; BIOS Fund III QP, LP; BIOS Fund III NT, LP
- Date
- 2026-10-28
- Code
- A
- Action
- Grant or award
- Quantity
- 269342
- Price
- 0
- Following holdings
- 269,342
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Warrant (Right to Buy)
- conversion Or Exercise Price: 0.5325
- transaction Date: 2026-10-28
- transaction Form Type: 4
- transaction Code: A
- equity Swap Involved: 0
- id: F1
- transaction Timeliness:
- transaction Shares: 269342
- transaction Price Per Share: 0
- transaction Acquired Disposed Code: A
- exercise Date: 2026-10-28
- id: F2
- expiration Date: 2031-10-28
- id: F2
- underlying Security Title: Common Stock
- underlying Security Shares: 269342
- shares Owned Following Transaction: 269342
- direct Or Indirect Ownership: I
- nature Of Ownership: Directly held by Bios Fund II QP, LP
- id: F3
- id: F4
- id: F5
Warrant (Right to Buy) (derivative)
- Owner
- BIOS Fund III, LP; BIOS Fund III QP, LP; BIOS Fund III NT, LP
- Date
- 2026-10-28
- Code
- A
- Action
- Grant or award
- Quantity
- 82454
- Price
- 0
- Following holdings
- 82,454
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Warrant (Right to Buy)
- conversion Or Exercise Price: 0.5325
- transaction Date: 2026-10-28
- transaction Form Type: 4
- transaction Code: A
- equity Swap Involved: 0
- id: F1
- transaction Timeliness:
- transaction Shares: 82454
- transaction Price Per Share: 0
- transaction Acquired Disposed Code: A
- exercise Date: 2026-10-28
- id: F2
- expiration Date: 2031-10-28
- id: F2
- underlying Security Title: Common Stock
- underlying Security Shares: 82454
- shares Owned Following Transaction: 82454
- direct Or Indirect Ownership: I
- nature Of Ownership: Directly held by Bios Fund II, LP
- id: F3
- id: F4
- id: F5
Warrant (Right to Buy) (derivative)
- Owner
- BIOS Fund III, LP; BIOS Fund III QP, LP; BIOS Fund III NT, LP
- Date
- 2026-10-28
- Code
- A
- Action
- Grant or award
- Quantity
- 133073
- Price
- 0
- Following holdings
- 133,073
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Warrant (Right to Buy)
- conversion Or Exercise Price: 0.5325
- transaction Date: 2026-10-28
- transaction Form Type: 4
- transaction Code: A
- equity Swap Involved: 0
- id: F1
- transaction Timeliness:
- transaction Shares: 133073
- transaction Price Per Share: 0
- transaction Acquired Disposed Code: A
- exercise Date: 2026-10-28
- id: F2
- expiration Date: 2031-10-28
- id: F2
- underlying Security Title: Common Stock
- underlying Security Shares: 133073
- shares Owned Following Transaction: 133073
- direct Or Indirect Ownership: I
- nature Of Ownership: Directly held by Bios Fund III NT, LP
- id: F3
- id: F4
- id: F5
Warrant (Right to Buy) (derivative)
- Owner
- BIOS Fund III, LP; BIOS Fund III QP, LP; BIOS Fund III NT, LP
- Date
- 2026-10-28
- Code
- A
- Action
- Grant or award
- Quantity
- 824012
- Price
- 0
- Following holdings
- 824,012
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Warrant (Right to Buy)
- conversion Or Exercise Price: 0.5325
- transaction Date: 2026-10-28
- transaction Form Type: 4
- transaction Code: A
- equity Swap Involved: 0
- id: F1
- transaction Timeliness:
- transaction Shares: 824012
- transaction Price Per Share: 0
- transaction Acquired Disposed Code: A
- exercise Date: 2026-10-28
- id: F2
- expiration Date: 2031-10-28
- id: F2
- underlying Security Title: Common Stock
- underlying Security Shares: 824012
- shares Owned Following Transaction: 824012
- direct Or Indirect Ownership: I
- nature Of Ownership: Directly held by Bios Fund III QP, LP
- id: F3
- id: F4
- id: F5
Warrant (Right to Buy) (derivative)
- Owner
- BIOS Fund III, LP; BIOS Fund III QP, LP; BIOS Fund III NT, LP
- Date
- 2026-10-28
- Code
- A
- Action
- Grant or award
- Quantity
- 126162
- Price
- 0
- Following holdings
- 126,162
- Reporting delay
- 2 days
- Filed terms and references
Filed terms
- security Title: Warrant (Right to Buy)
- conversion Or Exercise Price: 0.5325
- transaction Date: 2026-10-28
- transaction Form Type: 4
- transaction Code: A
- equity Swap Involved: 0
- id: F1
- transaction Timeliness:
- transaction Shares: 126162
- transaction Price Per Share: 0
- transaction Acquired Disposed Code: A
- exercise Date: 2026-10-28
- id: F2
- expiration Date: 2031-10-28
- id: F2
- underlying Security Title: Common Stock
- underlying Security Shares: 126162
- shares Owned Following Transaction: 126162
- direct Or Indirect Ownership: I
- nature Of Ownership: Directly held by Bios Fund III, LP
- id: F3
- id: F4
- id: F5
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- BIOS Fund III, LP: Director, 10% owner.
- BIOS Fund III QP, LP: Director, 10% owner.
- BIOS Fund III NT, LP: Director, 10% owner.
- F1: Pursuant to a letter agreement, dated as of October 2, 2026 and amended on October 16, 2026 (the "Letter Agreement"), between Actuate Therapeutics, Inc. (the "Issuer") and Bios Partners, L.P., on behalf of certain Bios entities (the "Bios Entities"), the Bios Entities agreed to a two-year lock-up of securities of the Issuer beneficially owned by them. In consideration thereof, the Issuer agreed to issue to the Bios Entities warrants to purchase an aggregate of 3,000,000 shares of common stock, par value $0.000001 per share (the "Common Stock"), at an exercise price of $0.5325 per share (the "Warrants"). The Warrants were issued at the closing of the Issuer's public offering.
- F2: A Warrant may be exercised only during the period ("Exercise Period") commencing on October 28, 2026 and terminating at 5:00 P.M., New York time on October 28, 2031 ("Expiration Date"). Each Warrant not exercised on or before the Expiration Date shall become void, and all rights thereunder and all rights in respect thereof under this Warrant Agreement shall cease at the close of business on the Expiration Date.
- F3: Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, LP ("Bios Fund I"), Bios Fund I QP, LP ("Bios Fund I QP") and BP Directors, LP ("BP Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, LP ("Bios Fund II"), Bios Fund II QP, LP ("Bios Fund II QP"), Bios Fund II NT, LP ("Bios Fund II NT") and Bios Actuate Co-Invest I, LP ("Bios Actuate Co-Invest I"). Bios Equity Partners III, LP ("Bios Equity III") is the general partner of the following entities: Bios Fund III, LP ("Bios Fund III"), Bios Fund III QP, LP ("Bios Fund III QP"), Bios Fund III NT, LP ("Bios Fund III NT"), Bios Actuate Co-Invest II, LP ("Bios Actuate Co-Invest II") and Bios Actuate Co-Invest III, LP ("Bios Actuate Co-Invest III"). Bios Equity COF, LP ("Bios Equity COF") is the general partner of Bios Clinical Opportunity Fund, LP ("Bios COF") and Bios 2024 Co-Invest.
- F4: Cavu Management, LP, an entity managed and controlled by Mr. Les Kreis, and Bios Capital Management, LP, an entity managed and controlled by Mr. Aaron Fletcher, are the general partners of Bios Equity I, Bios Equity II and Bios Equity III and Bios Capital Management, LP is the general partner of Bios Equity COF. Cavu Advisors LLC, an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management LP. Bios Advisors GP, LLC, an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Capital Management, LP.
- F5: The shares owned by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP, Bios Fund II NT, Bios Actuate Co-Invest I, Bios Fund III, Bios Fund III QP, Bios Fund III NT, Bios Actuate Co-Invest II, Bios Actuate Co-Invest III, Bios COF and Bios 2024 Co-Invest (collectively, the "Bios Equity Entities") are aggregated for purposes of reporting share ownership information. Mr. Kreis and Mr. Fletcher have voting and investment control with respect to shares held indirectly by Bios Advisors GP, LLC and Cavu Advisors, LLC, respectively.
Original sources
Prepared automatically from public filing data. Report a correction.